CompletedPhase 3NCT00146627
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Els Torreele, PhDDrugs for Neglected Diseases
- Intervention
- Eflornithine(drug)
- Enrollment
- 280 enrolled
- Eligibility
- 15-70 years · All sexes
- Timeline
- 2008
Study locations (4)
- MSF-Belgium; PNLTHA, Epicentre, Isangi, Democratic Republic of the Congo
- PNLTHA, STI, Epicentre, Katanda, Democratic Republic of the Congo
- PNLTHA, STI, Epicentre, Mbuyi Maji, Democratic Republic of the Congo
- MSF-Holland, Nkayi, RoC, Republic of the Congo
Collaborators
Medecins Sans Frontieres, Netherlands · PNLTHA-DRC; · PNLTHA-RoC · Epicentre · Swiss Tropical & Public Health Institute · World Health Organization
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00146627 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)